The financing round was led by Nutreco, Aqua-Spark and PFR Life Science, a portfolio company of the Polish Development Fund (PFR). Other investors in the round included Montis Capital, Seventure Partners as well as a group of Angel investors.
“The funds raised from investors will support the company’s efforts to reduce the use of antibiotics in livestock farming and to promote sustainable protein production and ultimately improve human health. We are proud that the potential of our company has attracted such a wide group of industry and financial investors who, like us, believe in the unique capabilities of bacteriophages,” explains Jarosław Dastych, CEO of Proteon Pharmaceuticals.
Matthew Tebeau, COO of Proteon Pharmaceuticals, adds “This investment increases our ability to make bacteriophages available to the global livestock and aquaculture markets, where they will increase the environmental sustainability of protein production as well as significantly reduce the need for antibiotics.”
Rob Koremans, Nutreco CEO says, “This investment underlines Nutreco’s commitment to our purpose of Feeding the Future and to the partnership between Proteon Pharmaceuticals and Nutreco’s aquaculture division Skretting. Together, Proteon Pharmaceuticals and Skretting are developing bacteriophage health products to support farmers in keeping their animals healthy without the use of antibiotics. Our investment is a great next step to deepen this ongoing relationship and to support Proteon Pharmaceuticals in this exciting phase in the company’s development.”
“With antibiotic resistance being one of biggest public health challenges of our time, it is imperative that we reduce the amount of antibiotics we use in animal farming. Proteon Pharmaceuticals is a leader in finding alternative, healthier ways to treat and prevent disease and we are proud to be a part of their current acceleration,” states Mike Velings and Amy Novogratz, Co-founders of Aqua-Spark.
“Investment in Proteon Pharmaceuticals is in line with the PFR Life Science strategy aiming at supporting Polish biotech companies with unique IP and strong potential to become global players. The company is well positioned to develop a new product category, that if successful, can contribute to lower antibiotics use which is a trend supported by regulators and consumers worldwide which PFR LS also believes in,” says Paweł Borys, CEO of the Polish Development Fund.
Wojciech Szwankowski, Montis Capital Managing Partner comments, “When you consider ambitious climate goals set by EU one cannot forget the challenge that food system accounts for a significant percent of global GHG emission and soil, water pollution. Proteon Pharmaceuticals’ bacteriophage technology is the necessary step in the fight against overuse of antibiotics in livestock farming but at the same time its usage reduces greenhouse emission with neutral impact on soil and water. For Montis Capital this investment is not only about financial return but also qualitative contribution to sustainable, green and health transformation, in line with EU 2050 agenda.”
Laëtitia Gerbe, Seventure Partners, mentions, “It is clear that the technology has potential to bring about a disruptive change in the animal production. We feel very enthusiastic about partnering with Proteon Pharmaceuticals’ team. Their experience in the sector and their extensive knowledge in the technology space will prove to be a winning combination to make the company one of the leading innovators globally in the field of animal health, to provide the industry with a totally new range of solutions.”
The company will use the funding to support a global product roll out and to support new product development. The investment will also help to further expand the capabilities of Proteon Pharmaceuticals’ microbiome platform technology. The platform will be developed through integration of Artificial Intelligence (AI) tools, high throughput screening and process automation, as well as expansion of production capacity.
Proteon Pharmaceuticals has developed bacteriophage cocktails that address Salmonella and Avian Pathogenic E. Coli infections in poultry production as well as Pseudomonas and Aeromonas infection in aquaculture. The company’s products are registered and commercially available in selected markets throughout Southeast Asia, South America, and Africa. Proteon Pharmaceuticals’ product development pipeline includes solutions for Mastitis in dairy cows and prevention of AHPND in shrimp production. The products are built using of natural bacteriophages in cocktails that are precision-designed using an AI-supported platform technology.
About Proteon Pharmaceuticals
Proteon Pharmaceuticals S.A. is a leader in bacteriophage (phage) technology for livestock farming and aquaculture. Proteon Pharmaceuticals mission is to eliminate the need for unnecessary antibiotic use, reducing the risk of antimicrobial resistance (AMR), as well as to increase the sustainability of protein production through the reduction of waste and improvement of on-farm efficiency. Our products function by modulating the microbiome enabling prophylactic health. We have created a precision phage product development platform that using -omics technologies, molecular biology, bioinformatics, and artificial intelligence (AI) to create effective, reliable, and safe antibacterial solutions for animal and human health.
For more information visit www.proteonpharma.com
Launched in 2014, Aqua-Spark is an investment fund with a mission to transform the global aquaculture industry into one that is healthier, more sustainable, and more accessible. They invest in aquaculture companies across the value chain—spanning farming operations, alternative feed ingredients, disease-battling technology, and consumer-facing aquaculture products. These companies are solving some of the industry’s big challenges while bringing returns that are comparable to today’s traditional industry. The portfolio works as an ecosystem, with the companies agreeing to collaborate on optimal solutions, and working together toward this shared vision of a more efficient global aquaculture industry.
Since 2015, the fund has invested in 22 complementary SMEs. Thus far, Aqua-Spark has EUR 250 million in assets under management, dedicated to investments in elements of the aquaculture industry that will make fish farming sustainable. The goal of the fund is to ultimately make sustainability widespread and profitable enough that it becomes the only way to farm fish.
About Montis Capital
Montis Capital is growth-oriented Venture Capital fund based in Poland, with a core mission to help founders create a sustainable future by developing products and technologies in Life Science and Industry 4.0 space. Within this mission, Montis Capital seeks to invest in great teams, scalable business models, and innovative and market-validated products at the growth stage. Montis Capital is led by Lukasz Dziekoński, Wojciech Szwankowski and Tomasz Poninski, who founded the firm in 2018 in Warsaw after years of international experience in banking, infrastructure, and life science.
Every day, Nutreco’s 12,300 dedicated employees in more than 37 countries across the globe relentlessly pursue our purpose of Feeding the Future in a way that ensures sustainability is front and centre in all we do. Our solutions go beyond nutrition – we provide best-in-class advice and technology to help our customers produce more food, in a sustainable way, to feed our growing population.
With over 100 years of experience, Nutreco is a global leader in animal nutrition through our Trouw Nutrition division, and in aquaculture through our Skretting division. Our NuFrontiers team works to identify, develop, and invest in next-generation breakthrough innovations throughout the value chain. In 2020, Nutreco had net revenues of €6.4 billion. The company is a subsidiary of SHV Holdings N.V., a family-owned multinational with net sales of €17 billion in 2020.
About Polish Development Fund
Polish Development Fund (PFR) is a group of financial and advisory institutions for entrepreneurs, local governments and individuals investing in the sustainable social and economic development of the country. Our priorities are infrastructure investments, innovation, business development, export and foreign expansion of Polish enterprises, support of local governments, implementation of the Employee Capital Plans program and support for foreign investment. We ensure effective coordination of development programs on the basis of an adapted strategy and integrated channels of contact with entrepreneurs, local governments, and individual clients.
PFR Life Science Sp. z o.o. is a portfolio company of one of the funds partially managed by PFR, whose purpose is to invest in biotech companies, those operating in the area of the development of innovative medicines, therapies, and technologies.
About Seventure Partners
With €850m net commitments under management as of the end of 2020, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has been investing in innovative businesses with high growth potential in two fields: Life sciences across Europe, Israel, Asia and North America, and Digital technologies mainly in France and Germany. In Life sciences, the main areas of focus include “classic” approaches such as biotechnology and pharmaceuticals, diagnostic and medtech, industrial biotechnology, as well as “beyond the pill” approaches such as MICROBIOME-linked innovations, nutrition, foodtech, digital/connected health and personalized medicine. Investments can range between €500k and €10m per round, and up to €20m per company, from early to late stage. In March 2018, Seventure Partners launched AVF, a fund dedicated to animal nutrition, feed, and health with Adisseo as strategic partner.
For more details: www.seventure.fr/en Twitter: @seventurep
Phages are the most abundant organisms on the planet. They are organic, natural, and omnipresent in the environment. A critical part of the global microbiome, phages naturally protect animals and humans from bacteria. Controlled delivery of phages, using precision biological tools, promises to reduce antibiotic usage, overcoming the growing threat of antibiotic resistant bacteria, as well as increasing sustainability in agriculture and improving human health.
For further information contact:
Adam Mickiewicz, Marketing Director, +48 515 956 232; firstname.lastname@example.org